DaxibotulinumtoxinA for Injection (DAXI) demonstrated prolonged duration of response for glabellar line reduction NEWARK, Calif. --(BUSINESS WIRE)--Dec. 5, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic

NEWARK, Calif. --(BUSINESS WIRE)--Dec. 4, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced the pricing of an underwritten public

NEWARK, Calif. ,--(BUSINESS WIRE)--Dec. 3, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public

- Appointment completes build-out of Revance’s commercial leadership team following submission of the Company’s Biologics License Application to the U.S. Food and Drug Administration for DaxibotulinumtoxinA for Injection (DAXI) - NEWARK, Calif. --(BUSINESS WIRE)--Dec.

NEWARK, Calif. --(BUSINESS WIRE)--Nov. 25, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today announced the Company has submitted a Biologics License Application (BLA) to

NEWARK, Calif. --(BUSINESS WIRE)--Nov. 12, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Stifel 2019 Healthcare Conference,

NEWARK, Calif. --(BUSINESS WIRE)--Nov. 6, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Credit Suisse 28th Annual Healthcare

– Conference call and webcast today at 4:30 p.m. ET – NEWARK, Calif. --(BUSINESS WIRE)--Nov. 4, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today reported financial results for the

- DaxibotulinumtoxinA for Injection (DAXI) has potential to be first long-acting neuromodulator for treatment of this debilitating involuntary muscle movement disorder - - Topline data expected in second half of 2020 - NEWARK, Calif. --(BUSINESS WIRE)--Nov. 4, 2019-- Revance Therapeutics, Inc.

- Results show DaxibotulinumtoxinA for Injection (DAXI) can reduce frown lines for 24 weeks (approximately 6 months) or more - NEWARK, Calif. --(BUSINESS WIRE)--Nov. 4, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for